Definium Therapeutics, Inc. (DFTX)

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study

Definium Reports Second Phase III Success in Anxiety Disorder Program

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript

Definium Therapeutics (DFTX) Achieves Positive Results in Phase 3 Study for DT120 ODT

Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript